Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk AsfiledCriticalNovo Nordisk As
Priority claimed from PCT/DK2002/000279external-prioritypatent/WO2002087605A2/en
Publication of BR0209403ApublicationCriticalpatent/BR0209403A/en
Medicines That Contain Protein Lipid Enzymes And Other Medicines
(AREA)
Abstract
"USO DE FVII MODIFICADO, E, MéTODO PARA TRATAR O DANO PULMONAR AGUDO OU A SìNDROME DA DOENçA RESPIRATóRIA AGUDA EM SERES HUMANOS". A presente invenção diz respeito ao uso do fator VII modificado para a fabricação de medicamentos para o tratamento do dano pulmonar agudo (ALI) ou da síndrome da angústia respiratória aguda (ARDS) em seres humanos."USE OF MODIFIED FVII, AND METHOD TO TREAT ACUTE LUNG DAMAGE OR ACUTE RESPIRATORY DISEASE SYNDROME IN HUMANS". The present invention relates to the use of modified factor VII for the manufacture of medicaments for the treatment of acute pulmonary injury (ALI) or acute respiratory distress syndrome (ARDS) in humans.
BR0209403-7A2001-05-022002-05-01
Modified fvii use, and, method for treating acute lung injury or acute respiratory disease syndrome in humans.
BR0209403A
(en)
A process for treating a mineral "active ingredient" with polysiloxane and fatty acid to produce h drophobic active ingredients and their use in polymerization for "breathable" films
Compound; process for the preparation of a compound; pharmaceutical composition; use of a compound; method for the treatment and prophylaxis of various disorders and obesity in a human